A股公告精选 | “20CM”4连板 创新药牛股三生国健(688336.SH)提示风险

Group 1 - Company Sanofi has entered into a collaboration with Pfizer for the 707 project, which involves a dual-targeting bispecific antibody product aimed at PD-1 and VEGF [1] - The collaboration allows Pfizer exclusive rights for development, production, and commercialization in regions outside mainland China [1] - The payment of sales milestone fees and royalties is contingent upon achieving specified sales targets, introducing uncertainty regarding actual revenue [1] Group 2 - Company Daqian Ecology announced that shareholders plan to reduce their holdings by up to 3.3% of the company's total shares [2] - Shareholder Anhui Xinhua Publishing Group intends to sell up to 407.16 million shares, while Vice General Manager Wang Zheng'an plans to sell up to 41.08 million shares [2] Group 3 - Company Sany Heavy Industry has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [3] - The application materials are in draft form and may be updated or revised as necessary [3] Group 4 - Company Xinhua Insurance plans to invest 10 billion yuan in the second phase of the Honghu Fund, which has a total size of 20 billion yuan [4] - The establishment of the fund is subject to regulatory procedures, introducing some uncertainty regarding its implementation [4] Group 5 - Company Zhongnan Media's subsidiary has signed a government procurement contract worth 1.009 billion yuan [6]